Biostatistician at Unlearn AI

San Francisco, California, United States

Unlearn AI Logo
$150,000 – $180,000Compensation
Senior (5 to 8 years)Experience Level
Full TimeJob Type
UnknownVisa
Healthcare, Technology, Artificial IntelligenceIndustries

Requirements

  • At least 2 years of experience at a pharmaceutical/biotech company or CRO supporting clinical trials
  • MS or PhD in Statistics or Biostatistics
  • Experience writing statistical analysis plans and collaboration (inferred from context)

Responsibilities

  • Define statistical analyses to utilize digital twins to improve the power and lower the sample size requirements of RCTs and to provide a comparator for single arm trials
  • Carry out internal and external case studies to utilize ML-based predictions in clinical trial applications
  • Work with customers in trial planning applications to use digital twins to select and optimize inclusion/exclusion criteria, endpoints, and simulate trial outcomes
  • Author regulatory documents such as SAP and protocol sections or briefing book contributions for clinical trials that use digital twins
  • Present to clients and prospective clients on statistical methodology using digital twins and results of analyses, and represent Unlearn to the broader scientific community
  • Collaborate with internal teams to develop evidence and test methodologies

Skills

Biostatistics
Machine Learning
Generative AI
Clinical Trials
Statistical Modeling
Patient Outcome Forecasting
Digital Twins

Unlearn AI

Creates AI-driven digital twins for healthcare

About Unlearn AI

Unlearn.AI creates digital twins of patients using artificial intelligence, which are virtual replicas that simulate potential health outcomes. This technology allows healthcare providers to predict how a patient's health may change over time, leading to more informed treatment decisions. The primary clients include healthcare providers and pharmaceutical companies, who can use these digital twins in clinical trials to simulate control groups, potentially speeding up drug development and approval processes. Unlearn.AI differentiates itself by offering a unique simulation technology that reduces the need for actual human control groups, which can save time and resources. The company's goal is to enhance decision-making in patient care and drug development through precise health outcome predictions.

San Francisco, CaliforniaHeadquarters
2017Year Founded
$127.1MTotal Funding
SERIES_CCompany Stage
AI & Machine Learning, HealthcareIndustries
51-200Employees

Benefits

Health Insurance
Dental Insurance
Vision Insurance
401(k) Retirement Plan
401(k) Company Match
Unlimited Paid Time Off
Paid Holidays
Commuter Benefits
Paid Parental Leave
Company Equity

Risks

Over-reliance on AI data may lead to inaccuracies in trial outcomes.
Increased competition from companies like Consilx and Aicure could impact market share.
High clinical trial failure rates could affect perception of Unlearn AI's effectiveness.

Differentiation

Unlearn AI's TwinRCT uses digital twins to enhance clinical trial precision.
The company offers TrialPioneer, a free tool for innovative trial design exploration.
Unlearn AI's digital twin technology reduces the need for human control groups.

Upsides

AI in clinical trials market expected to reach $2.74 billion by 2030.
Partnership with ProJenX highlights AI's potential in specific therapeutic areas.
TwinRCT 3.0 enhances decision-making in Phase II trials for better outcomes.

Land your dream remote job 3x faster with AI